Literature DB >> 29366522

Personalized Cancer Medicine: An Organoid Approach.

Hamidreza Aboulkheyr Es1, Leila Montazeri2, Amir Reza Aref3, Massoud Vosough1, Hossein Baharvand4.   

Abstract

Personalized cancer therapy applies specific treatments to each patient. Using personalized tumor models with similar characteristics to the original tumors may result in more accurate predictions of drug responses in patients. Tumor organoid models have several advantages over pre-existing models, including conserving the molecular and cellular composition of the original tumor. These advantages highlight the tremendous potential of tumor organoids in personalized cancer therapy, particularly preclinical drug screening and predicting patient responses to selected treatment regimens. Here, we highlight the advantages, challenges, and translational potential of tumor organoids in personalized cancer therapy and focus on gene-drug associations, drug response prediction, and treatment selection. Finally, we discuss how microfluidic technology can contribute to immunotherapy drug screening in tumor organoids.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  microfluidic technology; organoids; personalized cancer medicine; tumor modeling

Mesh:

Year:  2018        PMID: 29366522     DOI: 10.1016/j.tibtech.2017.12.005

Source DB:  PubMed          Journal:  Trends Biotechnol        ISSN: 0167-7799            Impact factor:   19.536


  63 in total

Review 1.  Humanized mice for immune checkpoint blockade in human solid tumors.

Authors:  Henry Yip; Carl Haupt; Grace Maresh; Xin Zhang; Li Li
Journal:  Am J Clin Exp Urol       Date:  2019-10-15

2.  Programmed cell death protein 1/programmed death ligand-1 checkpoint blockade meets patient-derived organoids.

Authors:  Lejia Sun; Huayu Yang; Yilei Mao
Journal:  Ann Transl Med       Date:  2019-12

3.  A Glioblastoma Genomics Primer for Clinicians.

Authors:  John D Patterson; Thidathip Wongsurawat; Analiz Rodriguez
Journal:  Med Res Arch       Date:  2020-02-21

Review 4.  ESR1 mutations in breast cancer.

Authors:  Derek Dustin; Guowei Gu; Suzanne A W Fuqua
Journal:  Cancer       Date:  2019-07-18       Impact factor: 6.860

Review 5.  Progress in Modeling Neural Tube Development and Defects by Organoid Reconstruction.

Authors:  Peng Li; Yongchang Chen
Journal:  Neurosci Bull       Date:  2022-06-26       Impact factor: 5.203

Review 6.  Three-dimensional cell culture: from evolution to revolution.

Authors:  Sharmin Alhaque; Michael Themis; Hassan Rashidi
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-07-05       Impact factor: 6.237

7.  Magnetic Fluid Hyperthermia as Treatment Option for Pancreatic Cancer Cells and Pancreatic Cancer Organoids.

Authors:  Julian Palzer; Benedikt Mues; Richard Goerg; Merel Aberle; Sander S Rensen; Steven W M Olde Damink; Rianne D W Vaes; Thorsten Cramer; Thomas Schmitz-Rode; Ulf P Neumann; Ioana Slabu; Anjali A Roeth
Journal:  Int J Nanomedicine       Date:  2021-04-23

8.  Brain Tumor Biobank Development for Precision Medicine: Role of the Neurosurgeon.

Authors:  Emilie Darrigues; Benjamin W Elberson; Annick De Loose; Madison P Lee; Ebonye Green; Ashley M Benton; Ladye G Sink; Hayden Scott; Murat Gokden; John D Day; Analiz Rodriguez
Journal:  Front Oncol       Date:  2021-04-26       Impact factor: 6.244

9.  Serine Metabolism Regulates YAP Activity Through USP7 in Colon Cancer.

Authors:  Xiaoya Zhao; Jianfei Fu; Bin Hu; Lin Chen; Jing Wang; Jinyong Fang; Chenyang Ge; Haiping Lin; Kailing Pan; Liang Fu; Lude Wang; Jinlin Du; Wenxia Xu
Journal:  Front Cell Dev Biol       Date:  2021-05-12

Review 10.  Organoids and Colorectal Cancer.

Authors:  Antonio Barbáchano; Asunción Fernández-Barral; Pilar Bustamante-Madrid; Isabel Prieto; Nuria Rodríguez-Salas; María Jesús Larriba; Alberto Muñoz
Journal:  Cancers (Basel)       Date:  2021-05-28       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.